AVAI, BIOA, NAGE, LLY, and NVO Lead a New Wave of Metabolic and Molecular Anti-Aging Therapies
Issued on behalf of Avaí Bio, Inc.
Companies mentioned in this article: Avaí Bio, Inc. (OTCQB: AVAI), BioAge Labs, Inc. (Nasdaq: BIOA), Niagen Bioscience, Inc. (Nasdaq: NAGE), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO)
Key Takeaways:
● Avaí Bio (OTCQB: AVAI) and joint venture partner Austrianova announced on April 7, 2026, that they will present the latest data from their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September, where Dr. Makoto Kuro-o — the scientist who discovered the Klotho gene — is among the featured researchers [1].
● The global anti-aging market generated more than $85 billion in 2025 with projections of nearly $120 billion by 2030, while the longevity biotech segment alone is forecast to expand from $9.86 billion in 2025 to roughly $29.7 billion by 2034 at a 12.84% compound annual growth rate [2][3].
● AVAI's joint venture with Austrianova — Klothonova — applies the clinically-validated Cell-in-a-Box® encapsulation platform to protect the genetically modified cells inside that produce the α-Klotho protein, a longevity protein whose decline with age has been linked in published research to cardiovascular, kidney, and cognitive function [1].
● Austrianova brings over 50 peer-reviewed publications and GMP-grade cell encapsulation expertise to the partnership, while AVAI's second program, Insulinova, targets diabetes — placing the company at the intersection of cell therapy and metabolic aging [1].
● The broader longevity and metabolic health landscape is accelerating: BIOA reported positive Phase 1 data showing an 86% median reduction in high-sensitivity CRP at Day 14 [4], NAGE surpassed 300 research material transfer agreements for its NAD+ precursor Niagen® [5], LLY received FDA approval on April 1, 2026 for Foundayo™ — the first oral GLP-1 pill for obesity that can be taken any time of day without food or water restrictions [6] — and NVO launched Wegovy® as the first oral GLP-1 pill for weight loss with UK NICE expanding access to 1.2 million patients for cardiovascular risk reduction [7][8].
LAS VEGAS — Baystreet.ca News Commentary — For decades, the anti-aging economy was dominated by creams, collagen powders, and multivitamins. That era is ending. A new generation of biotechnology and pharmaceutical companies is targeting the cellular, metabolic, and molecular drivers of aging itself — and the numbers reflect a market in transition. The global anti-aging market generated more than $85 billion in 2025 with projections approaching $120 billion by 2030, while the longevity biotech segment alone is forecast to expand from $9.86 billion in 2025 to nearly $29.7 billion by 2034 at a 12.84% compound annual growth rate [2][3]. Consumer-facing longevity platforms and longevity drug pipelines are both scaling rapidly.
At the cell-therapy end of that spectrum sits Avaí Bio, Inc. (OTCQB: AVAI), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging. On April 7, 2026, Avaí Bio announced that in collaboration with its joint venture partner Austrianova it will present the latest data from its α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September 2026 [1].
Representing Avaí Bio, Austrianova, and their joint venture Klothonova, Rahul Pawa — Chief Production Officer at Austrianova — will deliver the presentation during the September conference. The session will focus on the production of the longevity protein α-Klotho from encapsulated cells, an approach designed to sustainably restore circulating α-Klotho levels and support potential therapeutic applications in aging and related conditions [1].
The conference brings together a distinguished group of thought leaders at the forefront of Klotho science and innovation, including Dr. Makoto Kuro-o, the physician-scientist widely recognized for discovering the Klotho gene [1]. Klotho, first characterized in 1997, has since become one of the most studied longevity proteins in the world. Mice engineered to overexpress Klotho live significantly longer than wild-type controls, while Klotho-deficient mice show accelerated aging phenotypes. Circulating α-Klotho levels decline with age in humans and have been linked in published research to cardiovascular health, kidney function, and cognitive performance.
"We look forward to sharing the latest data from Klothonova's progress in α-Klotho production from encapsulated cells at this prestigious forum," said Brian Salmons, Chief Executive Officer of Austrianova [1]. He added that the company was honored to be invited by Harvard-trained neuroscientist Carmen Abrahams to participate in the conference and to present the latest data on production of α-Klotho using Cell-in-a-Box® alongside industry peers.
The Cell-in-a-Box® platform is clinically validated and commercially advanced. Austrianova, based in Singapore, is a leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies [1]. The technology encapsulates living, genetically modified cells in small cellulose-based capsules, allowing them to produce therapeutic proteins in the body while being protected from immune rejection.
Avaí Bio's strategy extends beyond the Klothonova program. The company's second program, Insulinova, targets diabetes — placing the company directly at the intersection of cell therapy and metabolic aging, two of the fastest-growing segments of the longevity economy. That positioning matters. As metabolic health is increasingly understood to be inseparable from biological aging itself, the line between diabetes drugs, obesity medicines, and longevity therapies is beginning to blur.
CONTINUED… Read this and more on Avaí Bio at: USANewsGroup.com/avai-profile/
In other industry developments:
BioAge Labs (Nasdaq: BIOA) — Targeting the Biology of Aging Itself With Novartis-Backed Longevity Platform
BioAge Labs reported full year 2025 financial results on March 24, 2026, detailing what management described as a defining period of clinical progress across its aging-biology platform [4]. The company's lead program, BGE-102, is an orally available small molecule NLRP3 inhibitor targeting the chronic inflammation linked to cardiovascular risk and metabolic dysfunction. In Phase 1 data reported in January 2026, BGE-102 at 120 mg once daily achieved an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at Day 14, with 93% of participants reaching hsCRP levels below 2 mg/L — a threshold associated with reduced cardiovascular risk [4]. BioAge was initiated with a Buy rating at Needham on March 27, 2026, reflecting analyst confidence in the company's pipeline [9]. The balance sheet is a key offset: cash, cash equivalents, and marketable securities totaled $285.1 million at year-end, supported by an underwritten offering completed in early 2026, giving management runway through 2029 [4]. BioAge also maintains a multi-year collaboration with Novartis worth up to $550 million, combining BioAge's longitudinal human aging cohorts tracked for up to 50 years with Novartis's expertise in exercise biology to discover new therapeutic targets for age-related diseases [10].
Niagen Bioscience (Nasdaq: NAGE) — NAD+ Research Leader Surpasses 300 Material Transfer Agreements and Doubles Buyback
Niagen Bioscience — formerly known as ChromaDex Corporation before its rebrand in March 2025 — is the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging [5]. On March 19, 2026, the company's board approved an increase to its share repurchase program, doubling the total authorization from $10 million to $20 million [11]. That followed Q4 2025 results on March 5 and a Canaccord Genuity Buy rating with a $13 price target, with the firm noting potential growth opportunities in the injectable segment [11]. Niagen Bioscience's external research program has now surpassed 300 material transfer agreements with investigators and research institutions around the world, contributing to 45 published clinical studies on Niagen® and making it what the company believes is the most extensively researched patented NAD-boosting ingredient in the world [5]. NAD+ is a coenzyme central to cellular energy production and DNA repair, and its decline with age is considered one of the core molecular signatures of aging biology — placing Niagen squarely in the molecular longevity conversation alongside cell-based approaches like Avaí Bio's.
Eli Lilly (NYSE: LLY) — FDA Approves Foundayo™, the First Anytime Oral GLP-1 Pill for Obesity
Eli Lilly announced on April 1, 2026 that the U.S. Food and Drug Administration approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems [6]. Foundayo is the first oral small molecule GLP-1 receptor agonist that can be taken any time of day without food or water restrictions, differentiating it from existing injectable GLP-1 therapies. In Phase 3 trials, the highest dose delivered an average of 12.4% weight loss [6]. The drug began shipping through LillyDirect® on April 6, 2026, with availability through U.S. retail pharmacies and telehealth providers shortly after [6]. Lilly has submitted orforglipron for weight management and/or Type 2 diabetes in more than 40 countries [12]. The strategic importance extends beyond obesity: GLP-1 receptor agonists are increasingly studied for their effects on cardiometabolic aging, insulin signaling, and inflammation — core drivers of age-related disease. The approval positions Lilly at the center of a rapidly expanding longevity-adjacent market that RBC Capital Markets analysts have repeatedly flagged as one of the most competitive pharmaceutical battlegrounds of the decade.
Novo Nordisk (NYSE: NVO) — Wegovy® Pill Launches as First Oral GLP-1 for Weight Loss, UK Expands Access to 1.2 Million Patients
Novo Nordisk launched the Wegovy® pill across the United States on January 5, 2026, following FDA approval on December 22, 2025 — the first oral GLP-1 medicine for obesity in the country [7]. In the OASIS 4 Phase 3 trial, once-daily oral semaglutide 25 mg demonstrated 16.6% mean weight loss when treatment was adhered to, comparable to the injectable form [7]. On March 19, 2026, the FDA also approved a higher-dose version of Wegovy — a 7.2 mg injectable — as Novo pushes to win back market share from rival Eli Lilly [13]. Then on April 1, 2026, England's drug price watchdog NICE recommended Wegovy to prevent heart attacks and strokes, significantly expanding National Health Service access to approximately 1.2 million additional people with established cardiovascular disease and overweight or obesity — the first GLP-1 backed for this cardiovascular use in the country [8]. Like Lilly, Novo Nordisk sits at the intersection of metabolic health and aging biology, where the same drug class that drives weight loss is also delivering cardiovascular risk reduction and an expanding list of cardiometabolic indications.
A longevity protein that declines with age. A clinically-validated encapsulation platform with GMP-grade manufacturing and over 50 peer-reviewed publications. A joint venture with one of the world's leading cell encapsulation specialists. An invitation to present alongside the scientist who discovered the Klotho gene. And a second program targeting diabetes — a disease increasingly understood as a core driver of biological aging. Avaí Bio, Inc. (OTCQB: AVAI) is advancing what may be one of the most differentiated small-cap approaches to the longevity opportunity in today's biotechnology market.
For more information on Avaí Bio, Inc. (OTCQB: AVAI), visit USANewsGroup.com
Read this and more news for Avaí Bio at: USANewsGroup.com/avai-profile/
Article Sources:
[1] https://www.newswire.ca/news-releases/avai-bio-and-austrianova-to-present-latest-data-on-klotho-anti-aging-therapy-at-annual-klotho-conference-830916646.html
[2] https://wewillcure.com/insights/company-profiles/anti-aging-and-longevity-startups-to-watch
[3] https://marketintelo.com/report/epigenetic-reprogramming-and-longevity-biotech-market
[4] https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-reports-full-year-2025-financial-results-and
[5] https://www.stocktitan.net/news/NAGE/niagen-bioscience-surpasses-300-external-research-agreements-from-717qjcgpyoi4.html
[6] https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html
[7] https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
[8] https://www.cnbc.com/2026/04/01/novo-nordisk-stock-wegovy-ozempic-nice-nhs-nvo.html
[9] https://www.cnbc.com/quotes/BIOA
[10] https://www.stocktitan.net/news/BIOA/bio-age-labs-announces-multi-year-collaboration-with-novartis-to-x5rl3lcgvejm.html
[11] https://www.insidermonkey.com/blog/canaccord-lowers-niagen-bioscience-inc-nage-pt-on-updated-forecasts-following-q4-results-1730607/
[12] https://www.statnews.com/2026/04/01/eli-lilly-obesity-pill-approved-orforglipron-foundayo/
[13] https://www.cnbc.com/2026/03/19/fda-approves-high-dose-version-of-novo-nordisks-obesity-drug-wegovy.html
CONTACT:
BAYSTREET.CA
cs@baystreet.ca
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. ("BAY"). BAY has been not been paid a fee for Avaí Bio, Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares of Avaí Bio, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avaí Bio, Inc. which were purchased in the open market. BAY and all of it's respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avaí Bio, Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Related Stories
